Illumina, Inc. $ILMN Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp reduced its holdings in Illumina, Inc. by 6.1%, owning 1,552,248 shares valued at approximately $123 million after selling 100,687 shares in the first quarter.
• Illumina reported $1.19 earnings per share for the most recent quarter, surpassing expectations, but also indicated a 4.8% decline in year-over-year revenue, totaling $1.06 billion.
• Research analysts currently have an average rating of "Hold" on Illumina’s stock, with a price target averaging $124.58, reflecting varying perspectives on its future performance.

Northern Trust Corp lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 6.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,552,248 shares of the life sciences company's stock after selling 100,687 shares during the quarter. Northern Trust Corp owned 0.98% of Illumina worth $123,155,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. grew its position in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares in the last quarter. Center for Financial Planning Inc. acquired a new position in shares of Illumina in the 1st quarter worth approximately $33,000. Fourth Dimension Wealth LLC acquired a new position in shares of Illumina in the 4th quarter worth approximately $40,000. PFS Partners LLC boosted its position in Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares during the period. Finally, Golden State Wealth Management LLC boosted its position in Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock valued at $42,000 after purchasing an additional 292 shares during the period. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Up 2.5%

Shares of Illumina stock opened at $101.80 on Friday. The business's fifty day moving average price is $98.18 and its two-hundred day moving average price is $89.13. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The company has a market capitalization of $15.65 billion, a P/E ratio of 12.89, a PEG ratio of 2.23 and a beta of 1.37. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 EPS. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ILMN. Guggenheim reduced their price objective on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Daiwa America lowered Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Wall Street Zen lowered Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. reduced their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Royal Bank Of Canada boosted their price objective on Illumina from $118.00 to $126.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. Seven equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina presently has an average rating of "Hold" and an average price target of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.